Proposed LCD - MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma (DL39585)

Litchman GH, Fitzgerald AL, Kurley SJ, Cook RW, Rigel DS. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.Curr Med Res Opin. 2020;36(8):1295-1300. doi:10.1080/03007995.2020.176328Rebeca T, Giselle P, Litchman GH, Rigel DS. Impact of gene expression profile testing on the management of squamous cell carcinoma by dermatologists.J Drugs Dermatol. 2019;18(10):980-984.Saleeby R, Bielinksi K, Fitzgerald A, Siegel J, Ibrahim S. A prospective, multi-center clinical utility study demonstrates that the 40-gene expression profile (40-GEP) test impacts clinical management for Medicare-eligible patients with high-risk cutaneous squamous cell carcinoma (cSCC).SKIN The Journal of Cutaneous Medicine.2022;6(6):482-496.Hooper PB, Farberg AS, Fitzgerald AL, et al. Real-world evidence shows clinicians appropriately use the prognostic 40-gene expression profile (40-GEP) test for high-risk cutaneous squamous cell carcinoma (cSCC) patients.Cancer Invest. 2022;40(10):911-922. doi:10.1080/07357907.2022.2116454Tokez S, Venables ZC, Hollestein LM, et al. Risk factors for metastatic cutaneous squamous cell carcinoma: refinement and replication based on 2 nationwide nested case-control studies.J Am Acad Dermatol. 2022;87(1):64-71. doi:10.1016/j.jaad.2022.02.056Part II head and neck. In: Amin MB, Edge S, Green F, et al., eds.AJCC Cancer Staging Manual. 8thed. Springer; 2018.Levine DE, Karia PS, Schmults CD. Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10-year single-institution cohort study.JAMA Dermatol. 2015;151(11):1220-1225. doi:10.1001/jamadermatol.2015.1702Eigentler TK, Leiter U, Hfner HM, Garbe C, Rcken M, Breuninger H. Survival of patients with cutaneous squamous cell carcinoma: results of a prospective cohort study.J Invest Dermatol. 2017;137(11):2309-2315. doi:10.1016/j.jid.2017.06.025Brantsch KD, Meisner C, Schnfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study.Lancet Oncol. 2008;9(8):713-720. doi:10.1016/S1470-2045(08)70178-5Roozeboom MH, Lohman BG, Westers-Attema A, et al. Clinical and histological prognostic factors for local recurrence and metastasis of cutaneous squamous cell carcinoma: analysis of a defined population.Acta Derm Venereol. 2013;93(4):417-421. doi:10.2340/00015555-1501Harb JN, Owens AL, Potter KM, Montuno M, De Jesus RO, Konda S. Resident rounds part III: case report: metastatic cutaneous squamous cell carcinoma in an African American female.J Drugs Dermatol. 2017;16(1):81-84.Harb JN, Owens AL, Potter KM, Montuno M, De Jesus RO, Konda S. Resident rounds part III: case report: metastatic cutaneous squamous cell carcinoma in an African American female.J Drugs Dermatol. 2017;16(1):81-84.Agbai ON, Buster K, Sanchez M, et al. Skin cancer and photoprotection in people of color: a review and recommendations for physicians and the public.J Am Acad Dermatol. 2014;70(4):748-762. doi:10.1016/j.jaad.2013.11.038Bradford PT. Skin cancer in skin of color.Dermatol Nurs. 2009;21(4):170-178.Battie C, Gohara M, Verschoore M, Roberts W. Skin cancer in skin of color: an update on current facts, trends, and misconceptions.J Drugs Dermatol. 2013;12(2):194-198.